Improve your understanding of the cardiopulmonary system with Essentials of Cardiopulmonary Physical Therapy, 4th Edition. Based on best practices prescribed in The Guide to Physical Therapist Practice, this new edition provides comprehensive coverage of anatomy, physiology, and cardiopulmonary assessment, along with expanded chapters on the growing topics of early mobilization of the ICU patient and acute care management. Using a practical approach, expert author Ellen Hillegass also discusses pathophysiology, pharmacology, and interventions in the outpatient setting.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Dedication - p. iii 6. Contributors - p. iv 7. Preface - p. vi 8. Acknowledgments - p. vii 9. Section 1. Anatomy and Physiology - p. vii 10. 1. Anatomy of the cardiovascular and pulmonary systems - p. 1 11. 2. Physiology of the cardiovascular and pulmonary systems - p. 23 12. Section 2. Pathophysiology - p. 41 13. 3. Ischemic cardiovascular conditions and other vascular pathologies - p. 42 14. Anatomy of the Coronary Arteries - p. 43 15. Myocardial Perfusion - p. 43 16. Atherosclerosis - p. 44 17. Hypertension - p. 58 18. Cerebrovascular Disease - p. 62 19. Peripheral Arterial Disease - p. 63 20. Other Vascular Disorders - p. 65 21. Summary - p. 68 22. 4. Cardiac muscle dysfunction and failure - p. 78 23. Causes and Types of Cardiac Muscle Dysfunction - p. 79 24. Cardiac Muscle - p. 86 25. Specific Pathophysiologic Conditions Associated with Congestive Heart Failure - p. 88 26. Clinical Manifestations of Congestive Heart Failure - p. 97 27. Medical Management - p. 104 28. Mechanical Management - p. 108 29. Surgical Management - p. 109 30. Prognosis - p. 110 31. Physical Therapy Assessment - p. 111 32. Physical Therapy Interventions - p. 112 33. Ventilation - p. 115 34. Summary - p. 117 35. 5. Restrictive lung dysfunction - p. 125 36. Etiology - p. 125 37. Pathogenesis - p. 125 38. Clinical Manifestation - p. 129 39. Maturational Causes of Restrictive Lung Dysfunction - p. 129 40. Interstitial Causes - p. 133 41. Environmental/Occupational Causes - p. 137 42. Asbestosis - p. 139 43. Infectious Causes - p. 140 44. Neoplastic Causes - p. 145 45. Pleural Diseases - p. 147 46. Cardiovascular Causes - p. 152 47. Neuromuscular Causes - p. 157 48. Musculoskeletal Causes - p. 163 49. Connective Tissue Causes of RLD - p. 166 50. Immunologic Causes - p. 170 51. Pregnancy as Cause - p. 172 52. Nutritional and Metabolic Causes - p. 173 53. Traumatic Causes - p. 174 54. Therapeutic Causes - p. 178 55. Pharmaceutical Causes - p. 181 56. Radiologic Causes - p. 183 57. Summary - p. 184 58. 6. Chronic obstructive pulmonary diseases - p. 187 59. 7. Cardiopulmonary implications of specific diseases - p. 214 60. Obesity - p. 214 61. Diabetes Mellitus - p. 227 62. Clinical Implications for Physical Therapy - p. 235 63. Chronic Kidney Disease and Failure - p. 238 64. Other Specific Diseases and Disorders - p. 241 65. Cardiopulmonary Toxicity of Cancer Treatment - p. 253 66. Summary - p. 256 67. Section 3. Diagnostic Tests and Procedures - p. 265 68. 8. Cardiovascular diagnostic tests and procedures - p. 266 69. Diagnostic Test Interpretation and Probability of Disease - p. 267 70. Sensitivity/Specificity of Testing - p. 267 71. Clinical Laboratory Studies - p. 267 72. Other Noninvasive Diagnostic Tests - p. 274 73. Other Imaging Modalities - p. 277 74. Exercise Testing - p. 279 75. Pharmacologic Stress Testing - p. 288 76. Cardiac Catheterization: Coronary Angiography and Ventriculography - p. 289 77. Digital Subtraction Angiography - p. 291 78. Endocardial Biopsy - p. 294 79. Vascular Diagnostic Testing for Aortic, Peripheral, and Carotid Disease - p. 294 80. Peripheral Arterial Disease and Dysfunction and Diagnosis - p. 295 81. Carotid Artery Disease and Diagnosis - p. 298 82. Summary - p. 299 83. 9. Electrocardiography - p. 305 84. 10. Pulmonary diagnostic tests and procedures - p. 338 85. Section 4. Surgical Interventions, Monitoring, and Support - p. 363 86. 11. Cardiovascular and thoracic interventions - p. 364 87. 12. Thoracic organ transplantation: Heart and lung - p. 386 88. History - p. 386 89. Evaluation - p. 388 90. Preoperative Rehabilitation - p. 393 91. Alternative Therapies to Transplantation - p. 395 92. Donor Selection and Matching Criteria - p. 399 93. Surgical Techniques - p. 399 94. Medications - p. 402 95. Postoperative Treatment - p. 403 96. Lung Transplantation - p. 409 97. Future Trends in Transplantation Care161 - p. 412 98. Summary - p. 415 99. 13. Monitoring and life support - p. 419 100. Section 5. Pharmacology - p. 444 101. 14. Cardiovascular medications - p. 445 102. Pharmacokinetics - p. 446 103. Pharmacodynamics - p. 448 104. General Considerations of Pharmacologic Management - p. 449 105. Cardiac Drugs Used in Critical Care - p. 475 106. Cardiac Pharmacology in the Geriatric Population - p. 478 107. Cardiac Pharmacology in the Neonate and Pediatric Populations - p. 480 108. Pharmacologic Management of Diabetes - p. 481 109. Heart Transplantation - p. 483 110. Vascular Pharmacology - p. 485 111. Summary - p. 486 112. 15. Pulmonary medications - p. 489 113. Section 6. Cardiopulmonary Assessment and Intervention - p. 505 114. 16. Examination and assessment procedures - p. 506 115. 17. Interventions for acute cardiopulmonary conditions - p. 539 116. 18. Interventions and prevention measures for individuals with cardiovascular disease, or risk of disease - p. 568 117. Primary Prevention - p. 569 118. Rehabilitation of Patients with Documented Cardiovascular Disease - p. 570 119. Management and Evaluation of Patients during the Acute Phase - p. 572 120. Postacute Phase Rehabilitation - p. 576 121. Candidacy - p. 576 122. Home-Based Cardiac Rehabilitation - p. 576 123. Rehabilitation/Secondary Prevention in the Outpatient Setting - p. 577 124. Secondary Prevention: Management of Risk Factors - p. 588 125. Administrative Considerations - p. 597 126. Summary - p. 601 127. 19. Pulmonary rehabilitation - p. 605 128. 20. Pediatric cardiopulmonary physical therapy - p. 626 129. 21. The lymphatic system - p. 650 130. 22. Outcome measures: A guide for the evidence-based practice of cardiopulmonary physical therapy - p. 674 131. Outcomes Defined - p. 675 132. Importance of Measuring Outcomes - p. 677 133. Selection of Data to Measure - p. 678 134. Functional Performance Measures - p. 690 135. Quality-of-Life Measures - p. 693 136. Summary - p. 696 137. Index - p. 703
Improve your understanding of the cardiopulmonary system with Essentials of Cardiopulmonary Physical Therapy, 4th Edition. Based on best practices prescribed in The Guide to Physical Therapist Practice, this new edition provides comprehensive coverage of anatomy, physiology, and cardiopulmonary assessment, along with expanded chapters on the growing topics of early mobilization of the ICU patient and acute care management. Using a practical approach, expert author Ellen Hillegass also discusses pathophysiology, pharmacology, and interventions in the outpatient setting.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Dedication - p. iii 6. Contributors - p. iv 7. Preface - p. vi 8. Acknowledgments - p. vii 9. Section 1. Anatomy and Physiology - p. vii 10. 1. Anatomy of the cardiovascular and pulmonary systems - p. 1 11. 2. Physiology of the cardiovascular and pulmonary systems - p. 23 12. Section 2. Pathophysiology - p. 41 13. 3. Ischemic cardiovascular conditions and other vascular pathologies - p. 42 14. Anatomy of the Coronary Arteries - p. 43 15. Myocardial Perfusion - p. 43 16. Atherosclerosis - p. 44 17. Hypertension - p. 58 18. Cerebrovascular Disease - p. 62 19. Peripheral Arterial Disease - p. 63 20. Other Vascular Disorders - p. 65 21. Summary - p. 68 22. 4. Cardiac muscle dysfunction and failure - p. 78 23. Causes and Types of Cardiac Muscle Dysfunction - p. 79 24. Cardiac Muscle - p. 86 25. Specific Pathophysiologic Conditions Associated with Congestive Heart Failure - p. 88 26. Clinical Manifestations of Congestive Heart Failure - p. 97 27. Medical Management - p. 104 28. Mechanical Management - p. 108 29. Surgical Management - p. 109 30. Prognosis - p. 110 31. Physical Therapy Assessment - p. 111 32. Physical Therapy Interventions - p. 112 33. Ventilation - p. 115 34. Summary - p. 117 35. 5. Restrictive lung dysfunction - p. 125 36. Etiology - p. 125 37. Pathogenesis - p. 125 38. Clinical Manifestation - p. 129 39. Maturational Causes of Restrictive Lung Dysfunction - p. 129 40. Interstitial Causes - p. 133 41. Environmental/Occupational Causes - p. 137 42. Asbestosis - p. 139 43. Infectious Causes - p. 140 44. Neoplastic Causes - p. 145 45. Pleural Diseases - p. 147 46. Cardiovascular Causes - p. 152 47. Neuromuscular Causes - p. 157 48. Musculoskeletal Causes - p. 163 49. Connective Tissue Causes of RLD - p. 166 50. Immunologic Causes - p. 170 51. Pregnancy as Cause - p. 172 52. Nutritional and Metabolic Causes - p. 173 53. Traumatic Causes - p. 174 54. Therapeutic Causes - p. 178 55. Pharmaceutical Causes - p. 181 56. Radiologic Causes - p. 183 57. Summary - p. 184 58. 6. Chronic obstructive pulmonary diseases - p. 187 59. 7. Cardiopulmonary implications of specific diseases - p. 214 60. Obesity - p. 214 61. Diabetes Mellitus - p. 227 62. Clinical Implications for Physical Therapy - p. 235 63. Chronic Kidney Disease and Failure - p. 238 64. Other Specific Diseases and Disorders - p. 241 65. Cardiopulmonary Toxicity of Cancer Treatment - p. 253 66. Summary - p. 256 67. Section 3. Diagnostic Tests and Procedures - p. 265 68. 8. Cardiovascular diagnostic tests and procedures - p. 266 69. Diagnostic Test Interpretation and Probability of Disease - p. 267 70. Sensitivity/Specificity of Testing - p. 267 71. Clinical Laboratory Studies - p. 267 72. Other Noninvasive Diagnostic Tests - p. 274 73. Other Imaging Modalities - p. 277 74. Exercise Testing - p. 279 75. Pharmacologic Stress Testing - p. 288 76. Cardiac Catheterization: Coronary Angiography and Ventriculography - p. 289 77. Digital Subtraction Angiography - p. 291 78. Endocardial Biopsy - p. 294 79. Vascular Diagnostic Testing for Aortic, Peripheral, and Carotid Disease - p. 294 80. Peripheral Arterial Disease and Dysfunction and Diagnosis - p. 295 81. Carotid Artery Disease and Diagnosis - p. 298 82. Summary - p. 299 83. 9. Electrocardiography - p. 305 84. 10. Pulmonary diagnostic tests and procedures - p. 338 85. Section 4. Surgical Interventions, Monitoring, and Support - p. 363 86. 11. Cardiovascular and thoracic interventions - p. 364 87. 12. Thoracic organ transplantation: Heart and lung - p. 386 88. History - p. 386 89. Evaluation - p. 388 90. Preoperative Rehabilitation - p. 393 91. Alternative Therapies to Transplantation - p. 395 92. Donor Selection and Matching Criteria - p. 399 93. Surgical Techniques - p. 399 94. Medications - p. 402 95. Postoperative Treatment - p. 403 96. Lung Transplantation - p. 409 97. Future Trends in Transplantation Care161 - p. 412 98. Summary - p. 415 99. 13. Monitoring and life support - p. 419 100. Section 5. Pharmacology - p. 444 101. 14. Cardiovascular medications - p. 445 102. Pharmacokinetics - p. 446 103. Pharmacodynamics - p. 448 104. General Considerations of Pharmacologic Management - p. 449 105. Cardiac Drugs Used in Critical Care - p. 475 106. Cardiac Pharmacology in the Geriatric Population - p. 478 107. Cardiac Pharmacology in the Neonate and Pediatric Populations - p. 480 108. Pharmacologic Management of Diabetes - p. 481 109. Heart Transplantation - p. 483 110. Vascular Pharmacology - p. 485 111. Summary - p. 486 112. 15. Pulmonary medications - p. 489 113. Section 6. Cardiopulmonary Assessment and Intervention - p. 505 114. 16. Examination and assessment procedures - p. 506 115. 17. Interventions for acute cardiopulmonary conditions - p. 539 116. 18. Interventions and prevention measures for individuals with cardiovascular disease, or risk of disease - p. 568 117. Primary Prevention - p. 569 118. Rehabilitation of Patients with Documented Cardiovascular Disease - p. 570 119. Management and Evaluation of Patients during the Acute Phase - p. 572 120. Postacute Phase Rehabilitation - p. 576 121. Candidacy - p. 576 122. Home-Based Cardiac Rehabilitation - p. 576 123. Rehabilitation/Secondary Prevention in the Outpatient Setting - p. 577 124. Secondary Prevention: Management of Risk Factors - p. 588 125. Administrative Considerations - p. 597 126. Summary - p. 601 127. 19. Pulmonary rehabilitation - p. 605 128. 20. Pediatric cardiopulmonary physical therapy - p. 626 129. 21. The lymphatic system - p. 650 130. 22. Outcome measures: A guide for the evidence-based practice of cardiopulmonary physical therapy - p. 674 131. Outcomes Defined - p. 675 132. Importance of Measuring Outcomes - p. 677 133. Selection of Data to Measure - p. 678 134. Functional Performance Measures - p. 690 135. Quality-of-Life Measures - p. 693 136. Summary - p. 696 137. Index - p. 703
